cross pathway validation with sar408701 Search Results


cross pathway validation with sar408701  (Sanofi)
86
Sanofi cross pathway validation with sar408701
The procedures for within-target validation (left side) and cross-pathway validation (right side) of the platform PBPK-QSP model originally developed for T-DM1. AD: Aggregate data; IPD: Individual patient data; mAb: monoclonal antibody; NHP: Non-human primates; PD: pharmacodynamics; PFS: progression-free survival; PK: pharmacokinetics; <t>SAR408701:</t> Tusamitamab ravtansine; (T-)Dxd: trastuzumab deruxtran;; : In vitro cell culture experiment; : In vivo mouse experiment; : In vivo NHP experiment; : Clinical trial data.
Cross Pathway Validation With Sar408701, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cross+pathway+validation+with+sar408701/med_rxiv__64898__2026__01__30__26345218-187-1-19?v=Sanofi
Average 86 stars, based on 1 article reviews
cross pathway validation with sar408701 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


The procedures for within-target validation (left side) and cross-pathway validation (right side) of the platform PBPK-QSP model originally developed for T-DM1. AD: Aggregate data; IPD: Individual patient data; mAb: monoclonal antibody; NHP: Non-human primates; PD: pharmacodynamics; PFS: progression-free survival; PK: pharmacokinetics; SAR408701: Tusamitamab ravtansine; (T-)Dxd: trastuzumab deruxtran;; : In vitro cell culture experiment; : In vivo mouse experiment; : In vivo NHP experiment; : Clinical trial data.

Journal: medRxiv

Article Title: Translational PBPK-QSP modeling platform for antibody-drug conjugates (ADC): within-target and cross-pathway validation to bridge preclinical and clinical results

doi: 10.64898/2026.01.30.26345218

Figure Lengend Snippet: The procedures for within-target validation (left side) and cross-pathway validation (right side) of the platform PBPK-QSP model originally developed for T-DM1. AD: Aggregate data; IPD: Individual patient data; mAb: monoclonal antibody; NHP: Non-human primates; PD: pharmacodynamics; PFS: progression-free survival; PK: pharmacokinetics; SAR408701: Tusamitamab ravtansine; (T-)Dxd: trastuzumab deruxtran;; : In vitro cell culture experiment; : In vivo mouse experiment; : In vivo NHP experiment; : Clinical trial data.

Article Snippet: For cross-pathway validation with SAR408701 (tusamitamab ravtansine), we thankfully acknowledge the provision of data from the ADC development at Sanofi, which are not publicly available, though.

Techniques: Biomarker Discovery, Drug discovery, In Vitro, Cell Culture, In Vivo